Interviews

The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.

Elizabeth Cherry discusses the need to break down silos between manufacturers and health systems specialty pharmacies through more transparent collaboration to better serve patients.

Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies

Sarah Butler discusses the important role pharmacists play in educating patients on these changes in medication prices.

Fran Gregory discusses the challenges posed by rising drug costs and emphasized that optimizing the use of biosimilars, which are entering the market at much lower prices than their reference products.

Jon Mahrt discusses strategies for improving patient access to medications through affordability initiatives and utilization management of high-cost drugs.

The Mental Health First Aid training can bring awareness in pharmacies.

Christie Smith discusses a medically integrated dispensing model that aligns the goals of patients, physicians, and pharmacists.

HSSPs improve medication adherence and reduce total health care costs by directly managing medications for complex chronic conditions like cancer, diabetes, COPD and CHF.

Tasmina Hydery, PharmD, BCGP, discusses how stakeholders can work together to generate and share real-world evidence on biosimilar effectiveness and switching in order to drive adoption and realize cost savings potential.

Shawn Riser Taylor, PharmD, CPP, CDCES, discusses the challenges and process of providing health care in a rural area of Guachipilincito in Honduras.

The use of artificial intelligence and real-time symptom monitoring integrate effectiveness of prescription digital therapeutics for mental health issues

Pharmacists play a key role in psychiatric medication overdose situations

Exploring challenges and opportunities in developing personalized treatments for schizophrenia

James Shehan shares insights on the promising trends shaping the weight loss medication and how changing views of obesity could pave the way for uptake GLP-1s.

Pharmacists can address social determinants to improve patient well-being and treatment.

Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.

Linking strong anticholinergic medications to increased risk of dementia in older adults

Potential for integration into care and future advancements for gaps in current schizophrenia treatments

Guidance on evaluating contraceptive options for patients with psychiatric conditions

New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.

Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder

Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia

The Librexia program includes 3 concurrent clinical trials, investigating milvexian’s use for ischemic stroke, acute coronary syndrome, and atrial fibrillation

James Shehan discusses the growth of the GLP-1 receptor agonist market for medicated-assisted weight loss.

Greg Baker, CEO of AffirmedRx, discusses the DRUG Act legislation and its potential impact on curbing rising drug costs through PBM reform.

Cristin Hackel discusses the current state of OTC contraception options, the differences between OTC and prescription methods, and how pharmacists can promote education and awareness.

Ron Lanton discusses California's Stop Dangerous Pharmacies Act, which aims to address understaffed chain pharmacies and reduce medication errors by implementing new regulations around pharmacy staffing, error reporting, and unsafe working conditions.

The podcast discusses how City of Hope Chicago fully integrates oncology pharmacists into care teams by positioning them in clinics, improving communication and collaboration to minimize delays for patients and enhance care delivery.

Sa'ed Al-Olimat, PharmD, also discussed the potentially groundbreaking shift for MDMA expected later in 2024.